You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 271 No. 10, March 9, 1994 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Commentary
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (68)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Statement on Use of DNA Testing for Presymptomatic Identification of Cancer Risk

National Advisory Council for Human Genome Research; Francis S. Collins, MD, PhD; Lennette J. Benjamin, MD; David Botstein, PhD; Jerome R. Cox, ScD; Norman Davidson, PhD; Joe W. Gray, PhD; Neil Holtzman, MD; David E. Housman, PhD; Kay R. Jamison, PhD; Rodney Rothstein, PhD; Diane C. Smith, PhD; Lloyd M. Smith, PhD; M. Anne Spence, PhD; Shirley M. Tilghman, PhD

JAMA. 1994;271(10):785.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

RECENT advances in the genetics of cancer have raised the possibility of widespread DNA testing for the detection of predisposition to cancer. This may allow individuals at high risk to avail themselves of preventive measures and potentially avoid early death. At least one company has already announced plans to begin offering testing for genetic cancer risk. While much alleviation of human suffering may eventually result from these advances in cancer genetics, a number of important questions must be addressed before widespread testing of this sort can be recommended.

Two relatively common heritable cancer risk genes have recently been located. Among people with colon cancer, it appears that as many as 10% carry an altered germline copy of a gene called MSH2.1-3 Individuals with an altered MSH2 gene face an approximately 80% risk of colon cancer; women also have an elevated risk of endometrial and ovarian cancer. Intense medical surveillance . . . [Full Text PDF of this Article]


Author Affiliations

National Institutes of Health, Bethesda, Md (chair); Monteflore Medical Hospital Center, Bronx, NY; Stanford (Calif) University; Washington University, St Louis, Mo; California Institute of Technology, Pasadena; University of California, San Francisco; Johns Hopkins University, Baltimore, Md (ad hoc); Massachusetts Institute of Technology, Cambridge; Johns Hopkins University, Baltimore, Md; Dorothy Nelkin; New York (NY) University; Columbia University, New York, NY; Bull Information Systems, Billerica, Mass; University of Wisconsin, Madison; University of California, Irvine; Princeton (NJ) University.

From the National Center for Human Genome Research, National Institutes of Health, Bethesda, Md. A complete list of the authors appears at the end of this article.


Footnotes

Reprint requests to the National Center for Human Genome Research, Bldg 38A, Room 617, National Institutes of Health, Bethesda, MD 20892 (Dr Collins).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1994 American Medical Association. All Rights Reserved.